California-based biotech company Ligand Pharmaceuticals has acquired CyDex Pharmaceuticals and its Captisol solubility-enhancing technology. CyDex's pipeline includes a Captisol-enhanced budesonide/azelastine nasal spray. Ligand will operate CyDex as a wholly-owned subsidiary. Read the company's press release. … [Read more...] about CyDex acquired by Ligand Pharmaceuticals
Business
Dutch court rules against GSK in Advair patent case
A court in The Hague has ruled in favor of Sandoz and Hexal, both units of Novartis, agreeing that the Dutch portion of GSK's European patent for Advair is not valid. GSK may appeal the ruling. Read a Reuters article. … [Read more...] about Dutch court rules against GSK in Advair patent case
Alexza says it will resubmit AZ-004 NDA in July 2011
According to Alexza Pharmaceuticals, it plans to resubmit its NDA for AZ-004 (Staccato loxapine) for the treatment of agitation in schizophrenic patients in July 2011. The company received a complete response letter (CRL) for the product from the FDA in October 2010. The FDA CRL cited safety concerns due to decreases in FEV1 after inhalation of a dose. Read the … [Read more...] about Alexza says it will resubmit AZ-004 NDA in July 2011
Indian company gets patent for anti-emetic nasal spray
According to reports, Lincoln Pharmaceuticals of Ahmedabad, India has been awarded an Indian patent for a nasal formulation of ondansetron hydrochloride intended to prevent nausea and vomiting for chemotherapy patients. The company says that it will begin marketing the product in India within the next few months and intends to market it internationally in the … [Read more...] about Indian company gets patent for anti-emetic nasal spray
Dance and Aerogen developing inhaled insuin product
Aerogen has licensed its OnQ nebulizer technology to a San Francisco, California company, Dance Pharmaceuticals for development of a new inhaled insulin solution product. Dance founder John S. Patton was a co-founder of Inhale Therapeutics, which later became Nektar and developed Exubera inhaled insulin. Read the companies' press release. … [Read more...] about Dance and Aerogen developing inhaled insuin product
Alkermes pulmonary delivery spin-out Civitas gets $20 million
Civitas Therapeutics has obtained $20 million in Series A financing for development of its lead product, a DPI intended for the treatment of Parkinson's disease. The assets Civitas has licensed from Alkermes include a pipeline, delivery technology, and a manufacturing facility. Management of the new company includes Glenn Batchelder, CEO; Richard Batycky, Chief … [Read more...] about Alkermes pulmonary delivery spin-out Civitas gets $20 million
Ritedose recalls albuterol inhalation solution vials in US
Contract manufacturer Ritedose has voluntarily recalled unit dose vials of albuterol inhalation solution due to mislabeling. The single dose vials contain a 2.5 mg/3 mL solution but are labeled as 0.5 mg/3 mL. The product was distributed across the United States and in Puerto Rico. Read the company's press release. … [Read more...] about Ritedose recalls albuterol inhalation solution vials in US
Intranasal insulin company CPEX acquired
A subsidiary of Footstar has entered into an agreement to acquire New Hampshire specialty pharma company CPEX, which is developing Nasulin intranasal insulin spray. Nasulin is in Phase 2 development, and CPEX has been seeking to license the product or to sell the program outright. Read the company's press release. … [Read more...] about Intranasal insulin company CPEX acquired
Procept and Ingeniatrics to team up on new spray dryer system
Belgian pharma equipment manufacturer Procept and Spanish tech company Ingeniatrics Tecnologías have signed an agreement to develop a new spray drying system based on Ingeniatrics' Flow Focusing technology, which is a "microfluidic technology capable of monodispersed droplet formation and manipulation, based on the production of capillary microjets that are … [Read more...] about Procept and Ingeniatrics to team up on new spray dryer system
Forest regains European rights to Colobreathe
Forest Laboratories has reached an agreement with Gruenenthal to reacquire the European rights to the Colobreathe colistin DPI for the treatment of P. aeruginosa infections in cystic fibrosis patients.The EMA is currently reviewing Forest's marketing application for the product. Read the company's press release. … [Read more...] about Forest regains European rights to Colobreathe